Lead Product(s) : IMC-C103C,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunocore Presents Ovarian Cancer Expansion Data For ImmTAC® Candidate IMC-C103C Targeting MAGE-A4
Details : The emerging IMC-C103C results, where most patients had either no or very low MAGE-A4 expression, are consistent with the RECIST and ctDNA reduction results reported for tebentafusp.
Product Name : IMC-C103C
Product Type : Antibody
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : IMC-C103C,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable